Group B streptococcal infection medical therapy

Jump to navigation Jump to search

Group B Streptococcal Infection Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Group B Streptococcal Infection from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Case Studies

Case #1

Group B streptococcal infection medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Group B streptococcal infection medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Group B streptococcal infection medical therapy

CDC on Group B streptococcal infection medical therapy

Group B streptococcal infection medical therapy in the news

Blogs on Group B streptococcal infection medical therapy

Directions to Hospitals Treating Group B streptococcal infection

Risk calculators and risk factors for Group B streptococcal infection medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]

Overview

Medical Therapy in Neonatal Meningitis

Empirical Antibiotic Therapy in Neonatal Meningitis

GBS should be suspected as a causative agent for bacterial meningitis in infants less than two years of age for whom empirical antibiotic therapy should be initiated immediately.

Shown below is a table depicting the choice of empirical medical therapy in neonatal meningitis.[1]

Age Possible pathogens causing the bacterial meningitis Empirical treatment
< 1 month Ampicillin + cefotaxime
OR
Ampicillin + aminoglycoside
1-23 months Vancomycin + third generation cephalosporin

Targeted Antibiotic Therapy in Neonatal Meningitis

Shown below is a table depicting the choice of targeted medical therapy in neonatal meningitis.[1]

Recommended therapy for GBS meningitis Alternative therapy for GBS meningitis
Ampicillin
OR
Penicillin
Consider adding an aminoglycoside
Third generation cephalosporin
(Ceftriaxone or cefotaxime)

Recommended Dosage of Antibiotics

Shown below is a table summarizing the recommended dosage of antibiotics according to the IDSA guidelines.[1]

Antibiotic agent Dosage
Amikacin 0-7 days: 15-20 mg/kg

8-28 days: 30 mg/kg


Infants > 28 days: 20-30 mg/kg

Ampicillin 0-7 days: 150 mg/kg

8-28 days: 200 mg/kg


Infants > 28 days: 300 mg/kg

Cefotaxime 0-7 days: 100-150 mg/kg

8-28 days: 150-200 mg/kg


Infants > 28 days: 225-300 mg/kg

Ceftazidime 0-7 days: 100-150 mg/kg

8-28 days: 150 mg/kg


Infants > 28 days: 150 mg/kg

Ceftriaxone Infants > 28 days: 80-100 mg/kg
Gentamicin 0-7 days: 5 mg/kg

8-28 days: 7.5 mg/kg


Infants > 28 days: 7.5 mg/kg

Penicillin G 0-7 days: 0.15 mg/kg

8-28 days: 0.2 mg/kg


Infants > 28 days: 0.3 mg/kg

Tobramycin 0-7 days: 5 mg/kg

8-28 days: 7.5 mg/kg


Infants > 28 days: 7.5 mg/kg

Vancomycin 0-7 days: 20-30 mg/kg

8-28 days: 30-45 mg/kg


Infants > 28 days: 60 mg/kg

Consider lower dosages and longer intervals of antibiotics in case of very low-birth weight neonates.

Medical Therapy for Pregnant Women

Asymptomatic Carriers

Treatment for GBS is indicated in cases of:

  • GBS bacteriuria during any trimester of the current pregnancy
  • Positive GBS vaginal-rectal screening culture in late gestation during current pregnancy

Intrapartum antibiotic treatment of asymptomatic pregnant women who are carriers of GBS because it provides prophylaxis against the transmission of the infection to the newborn.

Intrapartum antibiotic prophylaxis is not indicated in this circumstance if a cesarean delivery is performed before onset of labor on a woman with intact amniotic membranes.

The following are key components of intrapartum antibiotic prophylaxis agents and dosing:[2]

  • Penicillin remains the agent of choice for intrapartum antibiotic prophylaxis, with ampicillin as an acceptable alternative (AI).
  • Penicillin-allergic women at high risk for anaphylaxis should receive clindamycin if their GBS isolate is susceptible to clindamycin and erythromycin, as determined by antimicrobial susceptibility testing; if the isolate is sensitive to clindamycin but resistant to erythromycin, clindamycin may be used if testing for inducible clindamycin resistance is negative (CIII). Penicillin-allergic women at high risk for anaphylaxis should receive vancomycin if their isolate is intrinsically resistant to clindamycin as determined by antimicrobial susceptibility testing, if the isolate demonstrates inducible resistance to clindamycin, or if susceptibility to both agents is unknown (CIII).
  • The recommended dosing regimen of penicillin G is 5 million units intravenously, followed by 2.5--3.0 million units intravenously every 4 hours (AII). The range of 2.5--3.0 million units is recommended to achieve adequate drug levels in the fetal circulation and amniotic fluid while avoiding neurotoxicity. The choice of dose within that range should be guided by which formulations of penicillin G are readily available in order to reduce the need for pharmacies to specially prepare doses.

Chorioamnionitis

The treatment of chorioamnionitis requires the immediate administration of antibiotics until delivery:

References

  1. 1.0 1.1 1.2 Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM; et al. (2004). "Practice guidelines for the management of bacterial meningitis". Clin Infect Dis. 39 (9): 1267–84. doi:10.1086/425368. PMID 15494903.
  2. Verani J.R., McGee L, and Schrag S.J. Prevention of Perinatal Group B Streptococcal Disease. Revised Guidelines from CDC, 2010.CDC.gov

Template:Bacterial diseases


Template:WikiDoc Sources